JP2022506829A5 - - Google Patents
Info
- Publication number
- JP2022506829A5 JP2022506829A5 JP2021524438A JP2021524438A JP2022506829A5 JP 2022506829 A5 JP2022506829 A5 JP 2022506829A5 JP 2021524438 A JP2021524438 A JP 2021524438A JP 2021524438 A JP2021524438 A JP 2021524438A JP 2022506829 A5 JP2022506829 A5 JP 2022506829A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- breast cancer
- eribulin
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862758388P | 2018-11-09 | 2018-11-09 | |
| US62/758,388 | 2018-11-09 | ||
| PCT/US2019/061010 WO2020097625A1 (en) | 2018-11-09 | 2019-11-12 | Therapeutic regimens for treatment of cancer using eribulin and selective cdk4/6 inhibitor combinations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022506829A JP2022506829A (ja) | 2022-01-17 |
| JP2022506829A5 true JP2022506829A5 (cg-RX-API-DMAC7.html) | 2022-11-21 |
Family
ID=70612537
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021524438A Pending JP2022506829A (ja) | 2018-11-09 | 2019-11-12 | エリブリンと選択的cdk4/6阻害剤との組合せを使用する癌の処置のための治療レジメン |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20210267986A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3877422A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2022506829A (cg-RX-API-DMAC7.html) |
| CN (1) | CN113271977A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020097625A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL317919A (en) | 2016-12-05 | 2025-02-01 | G1 Therapeutics Inc | Preservation of immune response during chemotherapy regimens |
| JP7229162B2 (ja) | 2017-01-06 | 2023-02-27 | ジー1 セラピューティクス, インコーポレイテッド | 癌の治療に対する併用療法 |
| JP7853532B2 (ja) | 2020-05-19 | 2026-04-30 | ファーマコスモス ホールディング エー/エス | 医学的障害を治療するためのサイクリン依存性キナーゼ阻害化合物 |
| WO2022087018A1 (en) * | 2020-10-19 | 2022-04-28 | G1 Therapeutics, Inc. | Improved fluorouracil-based multi-agent chemotherapy for treatment of metastatic colorectal cancer |
| CN114748480B (zh) * | 2021-01-08 | 2023-10-20 | 轩竹生物科技股份有限公司 | 一种预防和/或治疗癌症的药物组合物 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102186969B1 (ko) * | 2010-10-25 | 2020-12-04 | 쥐원 쎄라퓨틱스, 인크. | Cdk 억제제 |
| AU2013353745A1 (en) * | 2012-12-04 | 2015-06-11 | Eisai R&D Management Co., Ltd. | Use of eribulin in the treatment of breast cancer |
| JP6430483B2 (ja) * | 2013-03-15 | 2018-11-28 | ジー1、セラピューティクス、インコーポレイテッドG1 Therapeutics, Inc. | 化学療法の間の正常細胞の一時的な保護 |
| RU2016136504A (ru) * | 2014-03-03 | 2018-04-03 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | ПРИМЕНЕНИЕ ЭРИБУЛИНА И ИНГИБИТОРОВ mTOR В КАЧЕСТВЕ КОМБИНИРОВАННОЙ ТЕРАПИИ ДЛЯ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННОГО НОВООБРАЗОВАНИЯ |
| WO2015161283A1 (en) * | 2014-04-17 | 2015-10-22 | G1 Therapeutics, Inc. | Tricyclic lactams for use in hspc-sparing treatments for rb-positive abnormal cellular proliferation |
| WO2015183961A1 (en) * | 2014-05-28 | 2015-12-03 | Eisai R&D Management Co., Ltd | Use of eribulin in the treatment of cancer |
| EP3191098A4 (en) * | 2014-09-12 | 2018-04-25 | G1 Therapeutics, Inc. | Combinations and dosing regimes to treat rb-positive tumors |
| US20160166536A1 (en) * | 2014-12-12 | 2016-06-16 | Northwestern University | Combination therapy for the treatment of cancer |
| US20160220569A1 (en) * | 2015-02-03 | 2016-08-04 | G1 Therapeutics, Inc. | CDK4/6 Inhibitor Dosage Formulations For The Protection Of Hematopoietic Stem And Progenitor Cells During Chemotherapy |
| WO2018005533A1 (en) * | 2016-07-01 | 2018-01-04 | G1 Therapeutics, Inc. | Antiproliferative pyrimidine-based compounds |
| JP2019524748A (ja) * | 2016-07-20 | 2019-09-05 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | がんの治療におけるエリブリン及びヒストンデアセチラーゼ阻害剤の使用 |
| IL317919A (en) * | 2016-12-05 | 2025-02-01 | G1 Therapeutics Inc | Preservation of immune response during chemotherapy regimens |
| JP7229162B2 (ja) * | 2017-01-06 | 2023-02-27 | ジー1 セラピューティクス, インコーポレイテッド | 癌の治療に対する併用療法 |
| EP3621633A2 (en) * | 2017-05-11 | 2020-03-18 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
| EP3654967A4 (en) * | 2017-07-21 | 2021-04-21 | Eisai R&D Management Co., Ltd. | USE OF EIBULIN AND CYCLINE-DEPENDENT KINASE INHIBITORS IN THE TREATMENT OF CANCER |
-
2019
- 2019-11-12 CN CN201980088426.8A patent/CN113271977A/zh active Pending
- 2019-11-12 JP JP2021524438A patent/JP2022506829A/ja active Pending
- 2019-11-12 WO PCT/US2019/061010 patent/WO2020097625A1/en not_active Ceased
- 2019-11-12 EP EP19881900.5A patent/EP3877422A4/en not_active Withdrawn
-
2021
- 2021-05-07 US US17/315,011 patent/US20210267986A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022031403A5 (cg-RX-API-DMAC7.html) | ||
| ES2561495T3 (es) | Régimen de tratamiento que utiliza neratinib contra cáncer de mama | |
| TWI873485B (zh) | 用於治療癌症之方法及包含cdk2抑制劑及cdk4抑制劑之給藥方案 | |
| CA3146346A1 (en) | 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid for use in metastatic or advanced breast cancer patients | |
| BR112020024062A2 (pt) | métodos para o tratamento de tumores de restos adrenais de testículo e de ovário | |
| BR112020010435A2 (pt) | uso de inibidor da parp no tratamento de câncer de ovário ou câncer de mama resistente à quimioterapia | |
| JP2019529581A5 (cg-RX-API-DMAC7.html) | ||
| CN106573042A (zh) | 治疗多发性骨髓瘤的药物组合 | |
| JP2017526695A5 (cg-RX-API-DMAC7.html) | ||
| TW202120096A (zh) | 使用包含atp競爭性akt抑制劑、cdk4/6抑制劑及氟維司群之組合療法治療乳癌 | |
| CN119997942A (zh) | 用于治疗癌症的化合物 | |
| JP2015517523A5 (cg-RX-API-DMAC7.html) | ||
| CN109069469A (zh) | 治疗癌症的方法 | |
| JP2019526632A5 (cg-RX-API-DMAC7.html) | ||
| CN111184863A (zh) | 酪氨酸激酶抑制剂、cdk4/6抑制剂、serd联合在制备治疗肿瘤的药物中的用途 | |
| JP2022506829A (ja) | エリブリンと選択的cdk4/6阻害剤との組合せを使用する癌の処置のための治療レジメン | |
| ES2841981T3 (es) | Antihistamínico para su uso en el tratamiento del cáncer de mama | |
| JP2013531073A5 (cg-RX-API-DMAC7.html) | ||
| JP5858989B2 (ja) | 組合せ | |
| JP2020521786A5 (cg-RX-API-DMAC7.html) | ||
| Chalasani | Optimizing quality of life in patients with hormone receptor-positive metastatic breast cancer: treatment options and considerations | |
| WO2019017497A1 (en) | USE OF CYCLIN-DEPENDENT KINASE ERIBULINE AND INHIBITORS IN THE TREATMENT OF CANCER | |
| JP2020517739A (ja) | リンパ節陽性の初期ホルモン受容体陽性かつヒト上皮成長因子受容体2陰性乳癌の補助治療のための内分泌療法とアベマシクリブとの組み合わせ | |
| JP2021138693A (ja) | がんを処置するための方法 | |
| JP2017502989A5 (cg-RX-API-DMAC7.html) |